Semax + Selank Dosage: 10mg/10mg Blend Vial Math

The Semax + Selank blend puts 10mg of each peptide in one vial, and the reported protocol is 1mg of each per administration. A widely circulated practitioner peptide reference lists both on the same schedule: 1mg subcutaneously in the morning, 2-3 days a week, for 8 weeks on and 8 weeks off. With 2mL of bacteriostatic water in a 10mg/10mg vial, one 20-unit draw holds 1mg of Semax and 1mg of Selank.

Each peptide has its own Russian clinical and laboratory record. The combination does not. No published study has given the two together, and nobody has reported how they hold up mixed in one vial. Below are the reported numbers, the split-dose math, and the evidence behind each half.

Research-context information only. Semax and Selank are research peptides. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

Semax is a synthetic analog of the ACTH(4-10) fragment (Dolotov et al., 2006, PMID 16996037). Selank is a synthetic analog of tuftsin, an immune peptide (Slominsky et al., 2017, PMID 28702721). Both are seven amino acids long and were developed in Russia.

Semax vs Selank: What Each Half Is

Community sources commonly describe the pairing as "one for focus, one for calm." The enzyme study shows the two also overlap on one pathway, so the blend is not purely two separate mechanisms.

Quick Reference: Practitioner-Reported Protocol

These values match the single-peptide protocols in our Semax dosing guide and Selank dosing guide. They come from the Jay Campbell / Hunter Williams practitioner cheat sheet, which lists both peptides at the same dose and schedule, not from a trial of the blend.

Cycling Details

The 2-3 days a week, 8-weeks-on and 8-weeks-off pattern is the practitioner reference's schedule for each peptide on its own. The blend inherits it because the two share identical lines in that reference. No study has tested a cycle length for either peptide by injection, or for the pair. The Russian clinical studies used short hospital or outpatient courses of the single peptides, not repeating cycles.

Routes of Administration

• Subcutaneous (SC): the route community sources describe for reconstituted lyophilized blend vials.
• Intranasal: the route used for both peptides in Russian clinical practice, which is why so much of the published work involves nasal administration. Some vendors sell Semax and Selank combinations as ready-made nasal sprays, a different product from the injectable vial.
• Intramuscular: rarely described in community sources for this blend.

The vial's concentration is set for injection math. Reported nasal and injected amounts are not interchangeable, and the clinical nasal doses below should not be read as injection doses.

Reconstitution Quick Reference

The community-circulated arithmetic: 10mg ÷ 2mL = 5mg/mL for each peptide. 1mg ÷ 5mg/mL = 0.2mL, or 20 units, and the same draw delivers 1mg of the other peptide, because the ratio is fixed at 1:1. By the same arithmetic, a 10mg/10mg vial holds ten 1mg + 1mg draws. Community notes describe swirling gently rather than shaking, then refrigerating at 2-8°C.

These figures report how community sources describe the arithmetic. They are not a preparation instruction. Vendors label these vials for research use only; the schedules on this page are community- and practitioner-reported, not labeled directions.

Affiliate disclosure: vendor links in this article are affiliate links. The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Ready to buy? Compare verified vendors on our best Semax + Selank blend sources page, or browse all coupon codes for up to 50% off.

Where These Numbers Come From

The 1mg + 1mg figure is a practitioner convention. The clinical record for each peptide uses different routes, doses and settings, and none of it involves the blend.

Semax in stroke. In a study of 30 patients with acute hemispheric ischemic stroke, compared with 80 conventionally treated controls, the most effective daily Semax doses were 12mg for moderate and 18mg for severe strokes. The courses lasted 5-10 days in hospital (Gusev et al., 1997, PMID 11517472). Those are acute-care doses in a specific disease, far above the community figure, and they do not translate to routine use.

Selank in anxiety. In 62 patients with generalized anxiety disorder or neurasthenia, 30 received Selank and the rest received the benzodiazepine medazepam. The investigators reported similar anxiolytic effects in both groups, plus additional anti-fatigue and stimulant-like effects with Selank. The abstract does not give the dose (Zozulia et al., 2008, PMID 18454096).

Side by side, never combined. Three Russian studies included both peptides, each as a separate arm:

• In human serum, both inhibited enkephalin-degrading enzymes, with Semax more potent (Kost et al., 2001, PMID 11443939).
• In healthy volunteers, resting-state fMRI after a single administration of Semax, Selank or placebo showed general and peptide-specific changes in connectivity between the right amygdala and the temporal cortex (Panikratova et al., 2020, PMID 32342318).
• In rats with a toxin-induced Parkinson's-like model, neither peptide changed motor activity, and Selank lowered anxiety-like behavior (Slominsky et al., 2017, PMID 28702721).

No study gave the two peptides together, and none measured their stability or degradation when mixed in one vial.

Product quality. Belgian regulators analyzing seized preparations identified Semax and Selank sold online as lyophilized powders and nasal sprays. The authors wrote that, to their knowledge, neither had completed any clinical trials (Vanhee et al., 2020, PMID 31667971). A blend COA that confirms the identity and amount of each peptide separately matters more for a two-peptide vial than for a single one.

Stacking Protocols

Because the vial fixes a 1:1 ratio, the stacking that community sources describe usually means adjusting one half with a separate vial, or adding a third peptide.

None of these combinations has been studied. The table reports community descriptions, not a regimen.

Side Effects & Safety

• No safety study of the combined blend exists. Its tolerability profile is inferred from each peptide on its own.
• In a mouse embryonic stem-cell model, Semax and Selank showed no toxic effect on cell proliferation or survival (Kobylyanskii et al., 2017, PMID 29063333). That is a cell model, not a human safety finding.
• The Selank anxiety trial reported effects comparable to medazepam. The abstract does not describe the adverse-event profile in detail.
• Injection-site redness and mild headache are the effects most often mentioned in self-reported community sources.
• Research vials are sold labeled "not for human consumption."